Cecilia Jones Joins LogicBio Therapeutics as Main Monetary Officer

LEXINGTON, Mass., Dec. 22, 2020 /PRNewswire/ — LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a scientific phase genetic medicines business, today introduced the appointment of Cecilia Jones as the Company’s chief money officer, efficient January 11, 2021. Matthias Jaffe, the present CFO at LogicBio, will phase down at the finish of the calendar year and will stay a guide to the Corporation throughout 2021.

“We are pretty delighted that Cecilia Jones, a chief with in depth working experience in strategic finance and company enhancement in the everyday living sciences sector, will be joining LogicBio as we enter an critical period of time of growth prospects for the Business,” mentioned Fred Chereau, LogicBio president and CEO. “We lately announced initiation of our stage 1/2 Dawn clinical trial for LB-001 in the treatment of methylmalonic acidemia and concluded a thriving abide by-on public presenting. As we expect supplemental key milestones in 2021, Cecilia will engage in a central job in supporting these significant initiatives and assisting LogicBio strategy for a broad vary of new enhancement opportunities.”

“I am thrilled to be becoming a member of LogicBio at this thrilling stage of the firm as they do the job to increase the access of genetic drugs,” explained Ms. Jones. “I look forward to joining the management crew and applying my practical experience in world finance to help the Corporation improve these chances in the several years ahead.”

Ms. Jones has much more than 20 decades of practical experience in consulting and economic management roles with major pharmaceutical and biotechnology providers. She is at the moment vice president for R&D, throughout the world medical and organization development finance, at Biogen, advising senior administration on expense prioritization to help the Company’s strategic objectives. At Biogen she formerly served as senior director corporate finance, in which she led world long-range scheduling and economic evaluation of business progress and M&A opportunities, and director of emerging marketplaces finance, exactly where she supported Latin America, Asia Pacific and Jap European marketplaces. Prior to joining Biogen, Ms. Jones was director intercontinental finance at Genzyme (now Sanofi Genzyme), the place she held different capabilities of raising obligation within intercontinental finance. She been given a Licenciatura en Economia from Universidad de San Andres in Buenos Aires, Argentina, and an MBA from Harvard Business School.

“On behalf of the board and administration team, I would like to extend our appreciation to Matthias Jaffe for his assistance as CFO at LogicBio for the duration of our formative decades and for his perseverance to doing the job with our crew as a specialist in the course of 2021 to guidance a sleek changeover,” Mr. Chereau additional.

About LogicBio Therapeutics

LogicBio Therapeutics is devoted to extending the arrive at of genetic medication with revolutionary platforms. LogicBio’s proprietary genome modifying technology platform, GeneRide, allows the web-site-distinct integration of a therapeutic transgene devoid of nucleases or exogenous promoters by harnessing the native process of homologous recombination. LogicBio has received Food and drug administration clearance for the very first-in-human medical demo of LB-001, a wholly owned genome enhancing plan leveraging GeneRide for the treatment method of methylmalonic acidemia. Individual enrollment in the period 1/2 Sunrise scientific trial is expected to start off in early 2021. In addition, LogicBio has a collaboration with Takeda to study and establish LB-301, an investigational treatment leveraging GeneRide for the therapy of the unusual pediatric sickness Crigler-Najjar syndrome.

LogicBio is also producing a Upcoming Era Capsid platform for use in gene enhancing and gene therapies. Details introduced have shown that the capsids supply hugely successful useful transduction of human hepatocytes with enhanced manufacturability with reduced stages of pre-existing neutralizing antibodies in human samples. Major-tier capsid candidates from this energy have demonstrated considerable enhancements around benchmark AAVs at the moment in medical advancement. LogicBio is establishing these remarkably powerful vectors for inside improvement candidates and possibly for business progress collaborations.

Ahead Wanting Statements

This press launch has “forward-looking” statements within just the which means of the federal securities guidelines, such as with regard to the Company’s administration changeover, upcoming improvement milestones and the timing of patient enrollment in the period 1/2 Sunrise clinical demo. These are not statements of historic specifics and are based mostly on management’s beliefs and assumptions and on data now out there. They are subject to hazards and uncertainties that could trigger the precise outcomes and the implementation of the Company’s options to vary materially, which include the pitfalls connected with the initiation, charge, timing, development and final results of the Company’s present and potential research and progress things to do and preclinical scientific tests and opportunity potential clinical trials. These threats are discussed in the Company’s filings with the U.S. Securities and Trade Fee (SEC), including, without having limitation, the Company’s Yearly Report on Sort 10-K filed on March 16, 2020, the Company’s Quarterly Report on Kind 10-Q submitted on May 11, 2020, and the Company’s subsequent filings with the SEC. Besides as needed by legislation, the Enterprise assumes no obligation to update these forward-hunting statements publicly, even if new facts gets readily available in the upcoming.

See primary content material to down load multimedia: http://www.prnewswire.com/information-releases/cecilia-jones-joins-logicbio-therapeutics-as-chief-financial-officer-301197292.html

Source LogicBio Therapeutics, Inc.